Orexo Full Year 2024 Earnings: EPS Misses Expectations

Orexo (STO:ORX) Full Year 2024 Results

Key Financial Results

• Revenue: kr590.0m (down 7.6% from FY 2023).
• Net loss: kr203.0m (loss widened by 58% from FY 2023).
• kr5.89 loss per share (further deteriorated from kr3.73 loss in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

ORX Post-Clinical Trial Products

• Pre-registration: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Orexo EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 28%.

The primary driver behind last 12 months revenue was the US Commercial segment contributing a total revenue of kr560.3m (95% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to kr340.0m (47% of total expenses). Explore how ORX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden.

Performance of the Swedish Pharmaceuticals industry.

The company's shares are down 4.8% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Orexo you should be aware of, and 1 of them is significant.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.